Advertisement

Candidiasis

  • Jack D. SobelEmail author
Chapter
Part of the Infectious Disease book series (ID)

Abstract

Multiple pathogenic species of Candida are responsible for a myriad of superficial and systemic or deep clinical syndromes that constitute candidiasis. Recent epidemiologic shifts in causative Candida species reflect the impact of use of several groups or classes of antimycotic drugs as well as the increase of at-risk and immunocompromised hosts. Newly introduced diagnostic tests facilitate earlier use of antifungal agents with improved clinical outcomes and reduced morbidity and mortality. The increased appearance of non-albicans Candida species has created an increased challenge to selecting early appropriate antifungal drug therapy. Since the introduction of the echinocandins class of drugs, no new drugs have been introduced and, new in vitro and clinical resistance of certain Candida species, notably Candida glabrata has emerged to this class as well, creating the need for more rapid species identification to ensure the rapid use of appropriate antimycotic therapy.

Keywords

Candida species Candidiasis Invasive candidiasis Candidemia Antifungal agents Drug resistance 

References

  1. 1.
    Calderone RA. Candida and candidiasis. Washington, DC: ASM Press; 2001.Google Scholar
  2. 2.
    Edwards JE. Candida species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th Ed. New York: Churchill Livingstone; 2001. p. 2938–57.Google Scholar
  3. 3.
    Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47:3149–54.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74:323–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703.CrossRefPubMedGoogle Scholar
  6. 6.
    Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Bodey GP, Anaissie EJ, Edwards JE. Definition of Candida infections. In: Bodey GP, editor. Candidiasis: pathogenesis, diagnosis, and treatment. New York: Raven Press Ltd; 1993. p. 407–9.Google Scholar
  10. 10.
    Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, Clark NM. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2012;67:707–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598–601.CrossRefPubMedGoogle Scholar
  13. 13.
    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309–16.CrossRefPubMedGoogle Scholar
  14. 14.
    Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Samonis G, Anaissie EJ, Rosenbaum B, Bodey GP. A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun. 1990;58:1514–7.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Yeo E, Alvarado T, Fainstein V, Bodey GP. Prophylaxis of oropharyngeal candidiasis with clotrimazole. J Clin Oncol. 1985;3:1668–71.PubMedGoogle Scholar
  17. 17.
    Kodsi BE, Wickremesinghe C, Kozinn PJ, Iswara K, Goldberg PK. Candida esophagitis: a prospective study of 27 cases. Gastroenterology. 1976;71:715–9.PubMedGoogle Scholar
  18. 18.
    Platt R, Polk BF, Murdock B, Rosner B. Risk factors for nosocomial urinary tract infection. Am J Epidemiol. 1986;24:977–85.Google Scholar
  19. 19.
    Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections—epidemiology. Clin Infect Dis. 2011;52(Suppl 6):S433–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000;30:14–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Kozinn PJ, Taschdjian CL, Goldberg PK, Wise GJ, Toni EF, Seelig MS. Advances in the diagnosis of renal candidiasis. J Urol. 1978;19:184–7.Google Scholar
  22. 22.
    Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet. 1989;2:1437–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses. 2012 55:e74–84.CrossRefPubMedGoogle Scholar
  24. 24.
    Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205.CrossRefPubMedGoogle Scholar
  25. 25.
    Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, Silveira FP, Kleiboeker SB, Clancy CJ. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240–8CrossRefPubMedGoogle Scholar
  26. 26.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35CrossRefPubMedGoogle Scholar
  27. 27.
    Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351:876–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Tuon FF, Amato VS, Penteado Filho SR. Bladder irrigation with amphotericin B and fungal urinary tract infection—systematic review with meta-analysis. Int J Infect Dis. 2009;13:701–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ, Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110–22.CrossRefPubMedGoogle Scholar
  30. 30.
    Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013 56:1724–32.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol. 2002;40:852–6.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller TM. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55:1352–61.CrossRefPubMedGoogle Scholar
  33. 33.
    Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52:648–53.CrossRefPubMedGoogle Scholar
  34. 34.
    Lingappan A, Wykoff CC, Albini TA, Miller D, Pathengay A, Davis JL, Flynn HW Jr. Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol. 2012;153:162–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Pfaller MA, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-h Clinical and Laboratory Standards Institute (CLSI) broth microdilution. J Clin Microbiol. 2011;49:630–7.CrossRefPubMedCentralPubMedGoogle Scholar

Suggested Reading

  1. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23:253–73.CrossRefPubMedCentralPubMedGoogle Scholar
  2. Calderone RA. Candida and candidiasis. Washington, DC: ASM Press, 2001.Google Scholar
  3. Clancy CJ, Nguyen MH. Finding the “missing 50 %” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284–92.CrossRefPubMedGoogle Scholar
  4. Edwards JE. Candida species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005:29398–2957.Google Scholar
  5. Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections—treatment. Clin Infect Dis. 2011;52(Suppl 6):S457–66.CrossRefPubMedGoogle Scholar
  6. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011 52:750–70.CrossRefPubMedGoogle Scholar
  7. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634–43.CrossRefPubMedGoogle Scholar
  8. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006;42:244–51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of Infectious DiseasesWayne State University School of Medicine, Harper University HospitalDetroitUSA

Personalised recommendations